Med Air Africa

medairafrica.com

Med Air Africa was founded with the vision to provide a higher level of medical care to clients in post-conflict and developing countries in Africa. Since our establishment in 2013, Med Air Africa has formed alliances with International Insurers and Assistance Companies by providing effective medical, aviation and logistic services to Government, NGOs and Mining Entities operating in Africa today. While our core focus is to provide effective health care solutions to the mining and exploration industry, our capacity to provide additional medical services grew during the Ebola outbreak in 2013.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

news image

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More

MedTech

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

news image

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More

Medical

FLUENT BIOSCIENCES AND NANOCELLECT ANNOUNCE JOINT COLLABORATION TO IMPROVE RESOLUTION OF SINGLE-CELL RNA SEQUENCING ANALYSIS OF RARE CELL POPULATIONS

Fluent BioSciences | June 18, 2022

news image

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations. Single-cell researchers are increasingly requiring scalable, flexible and ...

Read More

MedTech, Industrial Impact

INOVIO ANNOUNCES STRATEGIC REORGANIZATION TO DELIVER DNA MEDICINES TO PATIENTS

INOVIO Pharmaceuticals, Inc. | February 01, 2023

news image

On January 31, 2023, INOVIO, a leading biotechnology firm focused on the development and commercialization of DNA medicines to protect and treat people from cancer, HPV-associated diseases, and infectious diseases, announced a strategic reorganization to meet operational efficiency commitments and better position the company to deliver DNA medicines to patients. Following the previously announced end of clinical development projects in late 2022, the restructuring is estimated t...

Read More
news image

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More
news image

MedTech

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More
news image

Medical

FLUENT BIOSCIENCES AND NANOCELLECT ANNOUNCE JOINT COLLABORATION TO IMPROVE RESOLUTION OF SINGLE-CELL RNA SEQUENCING ANALYSIS OF RARE CELL POPULATIONS

Fluent BioSciences | June 18, 2022

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations. Single-cell researchers are increasingly requiring scalable, flexible and ...

Read More
news image

MedTech, Industrial Impact

INOVIO ANNOUNCES STRATEGIC REORGANIZATION TO DELIVER DNA MEDICINES TO PATIENTS

INOVIO Pharmaceuticals, Inc. | February 01, 2023

On January 31, 2023, INOVIO, a leading biotechnology firm focused on the development and commercialization of DNA medicines to protect and treat people from cancer, HPV-associated diseases, and infectious diseases, announced a strategic reorganization to meet operational efficiency commitments and better position the company to deliver DNA medicines to patients. Following the previously announced end of clinical development projects in late 2022, the restructuring is estimated t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us